PolyPid EBITDA 2019-2024 | PYPD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

PolyPid ebitda from 2019 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Historical Chart (TTM)

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$79.9B
Zoetis (ZTS)	$70.1B
Daiichi Sankyo, - (DSNKY)	$43.9B
Takeda Pharmaceutical (TAK)	$43.7B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$18.3B
Astellas Pharma (ALPMY)	$17.4B
United Therapeutics (UTHR)	$17B
Summit Therapeutics (SMMT)	$15.9B
Shionogi (SGIOY)	$12.3B
Neurocrine Biosciences (NBIX)	$11.4B
Corcept Therapeutics (CORT)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.5B
Orion OYJ (ORINY)	$7.4B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Stevanato Group S.p.A (STVN)	$6.2B
Grifols, S.A (GRFS)	$5.1B
Ionis Pharmaceuticals (IONS)	$5B
Ono Pharmaceutical (OPHLF)	$4.7B
Recursion Pharmaceuticals (RXRX)	$4.2B
Crinetics Pharmaceuticals (CRNX)	$3.4B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.4B
Hypermarcas (HYPMY)	$2.2B
Centessa Pharmaceuticals (CNTA)	$2.1B
Soleno Therapeutics (SLNO)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.8B
Evotec AG (EVO)	$1.6B
Ardelyx (ARDX)	$1.5B